(AOF) – Galapagos today announced that at its June 12, 2023 meeting, the Board of Directors co-opted Dr Susanne Schaffert as an independent non-executive director, replacing Dr Rajesh Parekh who stepped down. retired on June 10, 2023. The Belgian biotech underlines that its new recruit has behind her “an extraordinary 27-year career at Novartis”, having finished as President of Novartis Oncology and member of the Management Committee until her retirement in 2022, accelerating the internal product pipeline with 6 new clinical programs, multiple global launches.
Dr. Schaffert is also a board member of Incyte Corporation and Novo Holdings A/S, and a member of the Novo Advisory Group (NAG) and the Executive Education Board of St. Gallen Business School.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.